OBSOLETE: Bacterial susceptibility due to TLR signaling pathway deficiency Advocacy Hub | UniteRare

At a Glance

Live from database

1 event

Jul 1992

Halfan: FDA approved

Treatment of adults who can tolerate oral medication and who have mild to moderate malaria caused by Plasmodium falciparum or Plasmodium vivax.

FDAcompleted

Data from FDA regulatory filings and ClinicalTrials.gov. Updated periodically.

1 program

FINANCIAL LANDSCAPE SUMMARY

Total programs

Open now

Copay cards

Copay Assistance1

Halfan

SmithKline Beecham Pharmaceuticals

OpenContact for details

No active clinical trials currently recruiting for OBSOLETE: Bacterial susceptibility due to TLR signaling pathway deficiency.
Search all trials →

No recent news articles indexed yet for OBSOLETE: Bacterial susceptibility due to TLR signaling pathway deficiency.
Search PubMed for OBSOLETE: Bacterial susceptibility due to TLR signaling pathway deficiency →

No specialists currently listed for OBSOLETE: Bacterial susceptibility due to TLR signaling pathway deficiency.

View Disease Page

Full profile, treatments, community

Search Clinical Trials

Find recruiting studies now

Find Specialists

Ranked by expertise & trials

Financial Assistance

Copay cards, PAPs, grants